Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.
The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower low density lipoprotein (LDL) levels more so than others, while others may preferentially increase high density lipoprotein (HDL). Clinically, the choice of an agent depends on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the evidence-based guideline most recently updated in 2018 by the American College of Cardiology & American Heart Association.[1]
Investigational classes of hypolipidemic agents:
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
| |
---|---|
gastrointestinal tract / metabolism (A) |
|
blood and blood forming organs (B) |
|
cardiovascular system (C) |
|
skin (D) |
|
genitourinary system (G) |
|
endocrine system (H) |
|
infections and infestations (J, P, QI) |
|
malignant disease (L01–L02) |
|
immune disease (L03–L04) |
|
muscles, bones, and joints (M) |
|
brain and nervous system (N) |
|
respiratory system (R) |
|
sensory organs (S) |
|
other ATC (V) |
|
|
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GI tract |
| ||||||||||||
Liver |
| ||||||||||||
Blood vessels |
| ||||||||||||
Combinations |
| ||||||||||||
Other |
| ||||||||||||
|
Authority control databases: National |
|
---|